2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2384

Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
Abstract Number: 2385

Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 2387

Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
Abstract Number: 2388

Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort
Abstract Number: 2389

Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
Abstract Number: 2390

Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Abstract Number: 2391

Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Abstract Number: 2392

The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Abstract Number: 2393

Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Abstract Number: 2395

DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Abstract Number: 2396

DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
Abstract Number: 2397

Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Abstract Number: 2398

Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].